Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors

Authors: Lewis, K.D., Peris, K., Sekulic, A., Stratigos, A.J., Dunn, L., Eroglu, Z., Chang, A.L.S., Migden, M.R., Yoo, S.-Y., Mohan, K., Coates, E., Okoye, E., Bowler, T., Baurain, J.-F., Bechter, O., Hauschild, A., Butler, M.O., Hernandez-Aya, L., Licitra, L., Neves, R.I., Ruiz, E.S., Seebach, F., Lowy, I., Goncalves, P., Fury, M.G.

Source: In Annals of Oncology February 2024 35(2):221-228

Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma

Authors: Robert, C., Lewis, K.D., Gutzmer, R., Stroyakovskiy, D., Gogas, H., Protsenko, S., Pereira, R.P., Eigentler, T., Rutkowski, P., Demidov, L., Caro, I., Forbes, H., Shah, K., Yan, Y., Li, H., McArthur, G.A., Ascierto, P.A.

Source: In Annals of Oncology May 2022 33(5):544-555

Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up

Authors: D'Angelo, S.P., Bhatia, S., Brohl, A.S., Hamid, O., Mehnert, J.M., Terheyden, P., Shih, K.C., Brownell, I., Lebbé, C., Lewis, K.D., Linette, G.P., Milella, M., Xiong, H., Guezel, G., Nghiem, P.T.

Source: In ESMO Open December 2021 6(6)

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib

Authors: Ascierto, P.A., Lewis, K.D., Di Giacomo, A.M., Demidov, L., Mandalà, M., Bondarenko, I., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Simmons, B., Ye, C., Hooper, G., Wongchenko, M.J., Goodman, G.R., Yan, Y., Schadendorf, D.

Source: In Annals of Oncology January 2020 31(1):153-159

Ultrasonic Wave Scattering from Ellipsoidal Flaws in Metals

Authors: Adler, L., Lewis, K.D.

Source: 1977 Ultrasonics Symposium Ultrasonics Symposium, 1977. :44-47 1977

Relation: 1977 Ultrasonics Symposium

Survie à long terme chez les patients avec un mélanome avancé traités par NIVO et IPI dans l’étude CheckMate 067

Authors: Grob, J.J., Hodi, S., Chiarion-Sileni, V., Lewis, K.D., Rutkowski, P., Lao, C.D., Cowey, C.L., Schadendorf, D., Wagstaff, J., Dummer, R., Queirolo, P., Smylie, M., Butler, M.O., Hill, A.G., Márquez-Rodas, I., Haanen, J.B., Durani, P., Wang, P., Wolchok, J.D., Larkin, J.

Source: In Annales de Dermatologie et de Vénéréologie - FMC November 2022 2(8) Supplement 1:A130-A130

Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study.

Authors: Dummer, R., Guminksi, A., Gutzmer, R., Lear, J.T., Lewis, K.D., Chang, A.L.S., Combemale, P., Dirix, L., Kaatz, M., Kudchadkar, R., Loquai, C., Plummer, R., Schulze, H.‐J., Stratigos, A.J., Trefzer, U., Squittieri, N., Migden, M.R.

Source: British Journal of Dermatology; Jun2020, Vol. 182 Issue 6, p1369-1378, 10p

Subject Terms: BASAL cell carcinoma, PATIENT safety, MOHS surgery, RADIOTHERAPY

LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to hedgehog inhibitors (HHIs)

Authors: Stratigos, A.J., Sekulic, A., Peris, K., Bechter, O., Dutriaux, C., Kaatz, M., Lewis, K.D., Basset-Seguin, N., Chang, A.L.S., Dalle, S., Fernandez-Orland, A., Licitra, L., Robert, C., Ulrich, C., Hauschild, A., Migden, M.R., Dummer, R., Li, S., Bowler, T., Fury, M.G.

Source: In Annals of Oncology September 2020 31 Supplement 4:S1175-S1176

97P - Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC)

Authors: Rischin, D., Khushalani, N.I., Schmults, C.D., Guminski, A., Chang, A.L.S., Lewis, K.D., Lim, A.M., Hernandez-Aya, L., Hughes, B.G.M., Schadendorf, D., Hauschild, A., Stankevich, E., Booth, J., Li, S., Chen, Z., Desai, J., Lowy, I., Fury, M.G., Migden, M.R.

Source: In Annals of Oncology December 2019 30 Supplement 11:xi35-xi36

1240TiP - Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy

Authors: Lewis, K.D., Fury, M.G., Stankevich, E., Mathias, M., Mohan, K.K., Li, S., Nunnink, K., Perry, C., Narwal, A.

Source: In Annals of Oncology October 2018 29 Supplement 8

1142P - Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis

Authors: Ascierto, P.A., Ribas, A., Larkin, J., McArthur, G.A., Lewis, K.D., Hauschild, A., Flaherty, K.T., McKenna, E., Zhu, Q., Mun, Y., Dréno, B.

Source: In Annals of Oncology 1 October 2016 27 Supplement 6:vi391-vi391

1109PD - Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma

Authors: Hwu, P., Hamid, O., Gonzalez, R., Infante, J.R., Patel, M.R., Hodi, F.S., Lewis, K.D., Wallin, J., Mwawasi, G., Cha, E., Richie, N., Ballinger, M., Sullivan, R.

Source: In Annals of Oncology 1 October 2016 27 Supplement 6:vi380-vi380

Motion behavior of nauplii and early copepodid stages of marine planktonic copepods.

Authors: Paffenhöfer, G.-A., Strickler, J.R., Lewis, K.D., Richman, S.

Source: Journal of Plankton Research; Sep1996, Vol. 18 Issue 9, p1699-1715, 17p

Rates of ingestion and their variability between individual calanoid copepods: direct observations.

Authors: Paffenhöfer, G.-A., Bundy, M.H., Lewis, K.D., Metz, C.

Source: Journal of Plankton Research; Jul1995, Vol. 17 Issue 7, p1573-1585, 13p

Maternal Style in Reminiscing - The Revised Dimensions of Temperament Survey (DOTS-R)

Authors: Lewis, K.D.

Source: Cognitive Development; 1999, Vol. 14 Issue: 3 p381-399, 19p

FC11 Does systemic treatment prior to completion lymph node dissection influence surgical outcomes in stage III melanoma patients?

Authors: Kounalakis, N., Gonzalez, R., Becker, M.A., Lewis, K.D., Christenson, A., Pearlman, N., Robinson, W., McCarter, M.

Source: Melanoma Research; 2010 Supplement, Vol. 20, pe33-e34, 2p